Ann: DEP docetaxel positive phase 1 results, phase 2 commences, page-88

As was flagged at AGM

Starpharma will look to license DEP® docetaxel after completion of the first part of phase 2 or at the end of phase 2 unless a great deal is offered before.

It is also interesting to note - Bell Potter have a value of US $300 million on a DEP® docetaxel licensing transaction

And once again it cannot be overlooked - A split of the Sexual Wellness business (condoms, BV formulation, and other relevant technology) and Cancer Drug Delivery into 2 separate entities.

This would allow the likes of AstraZeneca an option to buy the latter of 2 in a clean deal (like the Agro technology just recent purchase)

That is not to say - AstraZeneca would not buy Starpharma lock, stock, and barrel and then hive off the Sexual Wellness part of business

To the question of how long - phase 2 - I will not look for the information - however will say that it was either mentioned in a video conference call, interview or maybe in conversation with CEO.

But does it really matter.

Timelines are not important - when talking about clinical trials

2 boxes have now been ticked

BV phase 3 trials completed and successful
DEP® docetaxel phase 1 trial completed and successful

Not too long before some more new exciting boxes and out of the blue announcements from Starpharma